文献速递淋巴瘤

局部霍奇金淋巴瘤EORTC/LYSA/FIL H10应答适应试验的长期随访

Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma.
PubMed 文献 · J Clin Oncol · 2023-11-15

该报告为H10试验预设的10年随访最终分析。在早期PET阴性的预后良好组,10年无进展生存率ABVD联合累及淋巴结放疗为98.8%,省略放疗为85.4%(HR 13.2,95%CI 3.1-55.8;非劣效P=0.9735,差异检验P<0.0001);预后不良组分别为91.4%和86.5%(HR 1.52,95%CI 0.84-2.75;非劣效P=0.8577,差异检验P=0.1628)。早期PET阳性患者中,标准ABVD与强化BEACOPPesc的PFS差异不再有统计学显著性(HR 0.67,95%CI 0.37-1.20,P=0.1777)。

要点

  • 早期PET阴性预后良好组:10年PFS ABVD联合INRT 98.8% vs 省略INRT 85.4%(HR 13.2;差异检验P<0.0001),支持ABVD联合INRT。
  • 早期PET阴性预后不良组:10年PFS ABVD联合INRT 91.4% vs 省略INRT 86.5%(HR 1.52;非劣效P=0.8577;差异检验P=0.1628)。
  • 早期PET阳性患者:标准ABVD与强化BEACOPPesc的PFS差异不再有统计学显著性(HR 0.67;95%CI 0.37-1.20;P=0.1777),强化治疗安全,未增加第二恶性肿瘤等晚期不良事件。

核心结论

  • 长期分析证实,在早期PET阴性患者中,省略累及淋巴结放疗与较低的10年PFS相关。
  • 在早期PET阳性患者中,标准方案与实验方案之间未出现显著差异,尽管BEACOPPesc强化治疗安全,未增加第二恶性肿瘤等晚期不良事件。

研究设计与样本

  • H10试验为应答适应治疗试验,本文报告预设的10年随访最终分析结果。

主要发现

  • 早期PET阴性预后良好组:10年PFS ABVD联合INRT为98.8%,省略INRT为85.4%(HR 13.2;95%CI 3.1-55.8;非劣效P=0.9735;差异检验P<0.0001),支持ABVD联合INRT。
  • 早期PET阴性预后不良组:10年PFS ABVD联合INRT为91.4%,省略INRT为86.5%(HR 1.52;95%CI 0.84-2.75;非劣效P=0.8577;差异检验P=0.1628)。
  • 早期PET阳性患者:标准ABVD与强化BEACOPPesc的PFS差异不再有统计学显著性(HR 0.67;95%CI 0.37-1.20;P=0.1777)。
  • BEACOPPesc强化治疗安全,未增加第二恶性肿瘤等晚期不良事件。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The primary analysis of the Early positron emission tomography (ePET) Response-Adapted Treatment in localized Hodgkin Lymphoma H10 Trial demonstrated that in ePET-negative patients, the risk of relapse increased when involved-node radiotherapy (INRT) was omitted and that in ePET-positive patients, switching from doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) to bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) significantly improved 5-year progression-free survival (PFS). Here, we report the final results of a preplanned analysis at a 10-year follow-up. In the favorable (F) ePET-negative group, the 10-year PFS rates were 98.8% versus 85.4% (hazard ratio [HR], 13.2; 95% CI, 3.1 to 55.8; P value for noninferiority = .9735; difference test P < .0001) in favor of ABVD + INRT; in the unfavorable (U) ePET-negative group, the 10-year PFS rates were 91.4% and 86.5% (HR, 1.52; 95% CI, 0.84 to 2.75; P value for noninferiority = .8577; difference test P = .1628). In ePET-positive patients, the difference in terms of PFS between standard ABVD and intensified BEACOPPesc was no longer statistically significant (HR, 0.67; 95% CI, 0.37 to 1.20; P = .1777). In conclusion, the present long-term analysis confirms that in ePET-negative patients, the omission of INRT is associated with lower 10-year PFS. Instead, in ePET-positive patients, no significant difference between standard and experimental arms emerged although intensification with BEACOPPesc was safe, with no increase in late adverse events, namely, second malignancies.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Federico M, Fortpied C, Stepanishyna Y, et al. Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma. J Clin Oncol. 2023. PMID: 37967311. doi:10.1200/JCO.23.01745

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。